Drug intelligence / Profile preview

CKDB-119

Development stage: Preclinical
Lead developer: CKD Bio

Overview

CKDB-119 is an experimental anti-cancer immune function enhancer currently in the research and development (R&D) phase, developed by CKD Bio. It is designed to function as an immunotherapy adjunct, potentially enhancing the body's immune response against cancer cells. As of the current pipeline data, it is categorized under the API (Active Pharmaceutical Ingredient) sector of CKD Bio's research, specifically targeting oncology through immune modulation. Detailed mechanistic information, such as its specific biological target or molecular modality, has not been publicly disclosed.

Beyond the preview

Go deeper on CKDB-119.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKDB-119.

Explore the full profile